Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15624094 | 0.93 | USP2 (0.51) | USP2SMN1; SMN2HPGDGPR119MEN1 | |
| SCHEMBL11913651 | 0.93 | USP2 (0.51) | USP2SMN1; SMN2HPGDGPR119MEN1 | |
| SCHEMBL173435 | 0.90 | USP2 (0.49) | USP2SMN1; SMN2HPGDGPR119MEN1 | |
| SCHEMBL293626 | 0.88 | USP2 (0.58) | USP2SMN1; SMN2HPGDGPR119MEN1 | |
| SCHEMBL25250236 | 0.86 | USP2 (0.56) | USP2SMN1; SMN2HPGDGPR119MEN1 | |
| Acetic Acid SCHEMBL27630753 | 0.86 | USP2 (0.45) | USP2SMN1; SMN2HPGDGPR119MEN1 | |
| SCHEMBL18294 | 0.84 | USP2 (0.69) | USP2SMN1; SMN2HPGDGPR119MEN1 | |
| SCHEMBL698803 | 0.84 | USP2 (0.69) | USP2SMN1; SMN2HPGDGPR119MEN1 | |
| SCHEMBL27906090 | 0.81 | USP2 (0.51) | USP2SMN1; SMN2HPGDGPR119MEN1 | |
| SCHEMBL2197203 | 0.81 | USP2 (0.51) | USP2SMN1; SMN2HPGDGPR119MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583858-B2 | TDO2 inhibitors | GENENTECH, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-12528828-B2 | Substituted pyrido[4,3-d]pyrimidines as KRAS modulators | ALTEROME THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4653425-A1 | METHOD FOR RAPIDLY PROVIDING PYRIDAZINES FROM TETRAZINES AND CIS-DIENOPHILES | Tetrakit Technologies ApS (DK) | 2025-11-26 | — | — | EP | disclosed |
| US-20250346610-A1 | SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS | ALTEROME THERAPEUTICS INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-12466842-B2 | Substituted pyrido [4,3-d]pyrimidines as KRAS modulators | ALTEROME THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| EP-4626555-A1 | GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | Tiger Biotherapeutics Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| US-20250282799-A1 | SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS | ALTEROME THERAPEUTICS, INC. | 2025-09-11 | — | — | US | disclosed |
| US-20250179093-A1 | KRAS MODULATORS | ALTEROME THERAPEUTICS, INC. | 2025-06-05 | — | — | US | disclosed |
| WO-2025064542-A1 | KRAS MODULATORS | ALTEROME THERAPEUTICS, INC. (US) | 2025-03-27 | — | — | WO | disclosed |
| US-20250092039-A1 | GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | TIGER BIOTHERAPEUTICS INC. | 2025-03-20 | — | — | US | disclosed |
| WO-2016164565-A1 | TRANS-CYCLOHEPTENES AND HETERO-TRANS-CYCLOHEPTENES FOR BIOORTHOGONAL COUPLING | UNIVERSITY OF DELAWARE (US) | 2016-10-13 | — | — | WO | disclosed |
| US-20160102094-A1 | Azaquinazoline Inhibitors of Atypical Protein Kinase C | IGNYTA, INC. (US) | 2016-04-14 | — | — | US | disclosed |
| US-20140113882-A1 | Azaquinazoline Inhibitors of Atypical Protein Kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-04-24 | — | — | US | disclosed |
| EP-1636217-B1 | 2-IMIDAZO-BENZOTHIAZOLES AS ADENOSINE RECEPTOR LIGANDS | HOFFMANN LA ROCHE (CH) | 2008-09-03 | — | — | EP | disclosed |
| EP-1636217-B1 | 2-IMIDAZO-BENZOTHIAZOLES AS ADENOSINE RECEPTOR LIGANDS | HOFFMANN LA ROCHE (CH) | 2008-09-03 | — | — | EP | disclosed |
| US-7122545-B2 | Imidazo-benzothiazoles | HOFFMANN-LA ROCHE INC. (US) | 2006-10-17 | — | — | US | disclosed |
| WO-2004101558-A1 | 2-IMIDAZO-BENZOTHIAZOLES AS ADENOSINE RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-25 | — | — | WO | disclosed |
| US-20040229862-A1 | Imidazo-benzothiazoles | F. HOFFMAN-LA ROCHE AG (CH) | 2004-11-18 | — | — | US | disclosed |
| EP-0856002-A1 | PHENYLOXAZOLIDINONES HAVING A C-C BOND TO 4-8 MEMBERED HETEROCYCLIC RINGS | PHARMACIA & UPJOHN COMPANY (US) | 1998-08-05 | — | — | EP | disclosed |
| WO-1997009328-A1 | PHENYLOXAZOLIDINONES HAVING A C-C BOND TO 4-8 MEMBERED HETEROCYCLIC RINGS | PHARMACIA & UPJOHN COMPANY (US) | 1997-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179093-A1 | KRAS MODULATORS | KRAS, NRAS, HRAS | USP2 1013/4885SMN1; SMN2 3622/4885HPGD 2680/4885 |
| US-12583858-B2 | TDO2 inhibitors | TDO2, IDO2, TPH2 | USP2 1181/4885SMN1; SMN2 4338/4885HPGD 482/4885 |
| US-20250092039-A1 | GLUTARIMIDE-CONTAINING PAN-KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF | KRAS, VHL, HRAS | USP2 100/4885SMN1; SMN2 2182/4885HPGD 621/4885 |
| US-20250346610-A1 | SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS | KRAS, NRAS, HRAS | USP2 2827/4885SMN1; SMN2 2585/4885HPGD 1094/4885 |
| US-12466842-B2 | Substituted pyrido [4,3-d]pyrimidines as KRAS modulators | KRAS, NRAS, HRAS | USP2 2827/4885SMN1; SMN2 2585/4885HPGD 1094/4885 |
| US-20160102094-A1 | Azaquinazoline Inhibitors of Atypical Protein Kinase C | PRKCQ, PRKCZ, PRKCE | USP2 2405/4885SMN1; SMN2 4304/4885HPGD 4529/4885 |
| US-20140113882-A1 | Azaquinazoline Inhibitors of Atypical Protein Kinase C | PRKCQ, PRKCZ, PRKCE | USP2 2373/4885SMN1; SMN2 4405/4885HPGD 4473/4885 |
| US-20250282799-A1 | SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORS | KRAS, NRAS, HRAS | USP2 2827/4885SMN1; SMN2 2585/4885HPGD 1094/4885 |
| US-12528828-B2 | Substituted pyrido[4,3-d]pyrimidines as KRAS modulators | KRAS, NRAS, HRAS | USP2 3777/4885SMN1; SMN2 2906/4885HPGD 2903/4885 |
| US-20040229862-A1 | Imidazo-benzothiazoles | ADORA1, ADORA3, ADORA2A | USP2 4573/4885SMN1; SMN2 3421/4885HPGD 3325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.